Browsing Tag
Hart-Scott-Rodino Act
6 posts
Merck’s $6.7bn Terns deal moves closer as TERN trades near offer price
Merck cleared a deal hurdle. TERN-701 now has to show whether one CML asset can justify a $6.7bn oncology bet.
WBD stock sits near $27 as $31 Paramount offer clears shareholder vote: Inside the merger arb gap and regulatory risk
WBD shareholders approve $110bn Paramount Skydance takeover. What the deal means for Hollywood, media consolidation, and the regulatory road ahead.
SunOpta’s Refresco sale is closer now, but the real closing risk has not fully disappeared
SunOpta has cleared a major antitrust hurdle in its Refresco buyout. Read what the approval changes, what risks remain, and what it means for STKL.
NVRI near 52-week high as Enviri clears final regulatory hurdle for $3.04bn Clean Earth sale to Veolia
Enviri (NVRI) clears HSR antitrust review for $3B Clean Earth sale to Veolia. SEC filings due this month. What happens next for NVRI investors? Read more.
Merger war explodes: Pfizer drags Metsera and Novo Nordisk to court over ‘illegal’ bid
Pfizer takes legal action against Metsera and Novo Nordisk over breach of merger terms. Find out how this battle could reshape obesity drug M&A.
Merck licenses innovative anti-cancer therapy LM-299 from LaNova Medicines
In a strategic move to broaden its oncology portfolio, Merck & Co., Inc. (NYSE: MRK), recognized globally as…